Recruiting × INDUSTRY × Fallopian Tube Neoplasms × Clear all A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
DUAL-OV-CAR-NK
Phase 1/2 Recruiting
36 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
GLORIOSA
Phase 3 Recruiting
520 enrolled
ELUCIDATE
Phase 1/2 Recruiting
230 enrolled
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Recruiting
24 enrolled
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Phase 1 Recruiting
90 enrolled
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2/3 Recruiting
860 enrolled
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Phase 2 Recruiting
110 enrolled
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Phase 1/2 Recruiting
60 enrolled
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2 Recruiting
230 enrolled
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1/2 Recruiting
890 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2 Recruiting
612 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
ORACLE
Recruiting
2,020 enrolled
BARHYSTER
Recruiting
132 enrolled
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 3 Recruiting
450 enrolled
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 Recruiting
50 enrolled
A Study of ZN-c3 in Patients With Ovarian Cancer
Phase 1 Recruiting
140 enrolled
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 Recruiting
460 enrolled